|
|
|
|
|
|
Moving a large-molecule therapy toward commercialization requires more than scaling a manufacturing process. Formulation, technology transfer, capacity, supply continuity, and sterile fill-finish must work together to protect product quality and keep increasingly complex programs moving forward.
Making these decisions earlier can help sponsors identify potential bottlenecks, establish more robust processes, and better prepare for the transition from clinical to commercial supply. In this edition of the Outsourced Pharma Capabilities Update (OPCU), hear from CDMOs addressing key considerations across large molecule manufacturing and fill-finish, from process development and technology transfer to aseptic operations and scale-up. Watch the presentations below for perspectives on building a manufacturing strategy that can adapt as your program advances.
Recent Sessions Available On-Demand
AI Drug Manufacturing & Viral Vectors – October 2026
mRNA & Packaging, Labeling & Logistics – October 2026
Fill/Finish – October 2026
ADC – October 2026
Upcoming OPCU Topics & Times
Enabling ADC Success | 12/1/2026, PM Session
Mastering Aseptic Fill-Finish | 12/1/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
|
|
|
|
|
|
Thermo Fisher Scientific
|
Learn how to balance technical, regulatory, and supply chain considerations while avoiding costly late-stage changes and preparing for successful technology transfer, scale-up, and commercialization.
|
|
Request Information
|
|
Thermo Fisher Scientific
|
|
|
|
Lonza
|
Bastian Klöfer, Director of Commercial Development, Drug Product Services, explores Lonza's end-to-end biologics network, spanning drug substance, drug product development, manufacturing, analytics and regulatory support.
|
|
Request Information
|
|
Lonza
|
|
|
|
Simtra Biopharma Solutions
|
Explore new sterile manufacturing capacity for pre-filled syringes, lyophilized vials, and potent therapies, supporting flexibility, scale, and supply resilience.
|
|
Request Information
|
|
Simtra BioPharma Solutions
|
|
|
|
PCI Pharma Services
|
PCI integrates scalable manufacturing, packaging, device assembly, and global regulatory expertise to streamline tech transfer and strengthen supply chain resilience.
|
|
Request Information
|
|
PCI Pharma Services
|
|
|
|
Alcami
|
Discover critical considerations for sterile fill-finish, including manufacturability, scale-up, contamination control, and the path from clinical to commercial supply.
|
|
Request Information
|
|
Alcami
|
|
|
|
|
|
Lonza
|
Ben Neunstoecklin, Director of Commercial Development, provides an overview of biologics drug substance manufacturing capabilities and global network capacity that supports customer programs from development through commercial supply.
|
|
Request Information
|
|
Lonza
|
|
|
|
Cytovance Biologics
|
Move biologics from research and development toward commercialization with integrated development, analytics, scalable GMP manufacturing, and early-phase fill-finish capabilities.
|
|
Request Information
|
|
Cytovance Biologics
|
|
|
|
|
|
Coriolis Pharma
|
Integrated drug product development helps biopharma teams identify risks early, optimize formulation and manufacturing, and create stable, scalable biologics ready for clinical and commercial success.
|
|
Request Information
|
|
Coriolis Pharma
|
|
|
|
3PBIOVIAN
|
Integrated CDMO services for biologics and advanced therapies, offering plasmid DNA, viral vectors, fill-finish, and scalable manufacturing from development through commercialization.
|
|
Request Information
|
|
3PBIOVIAN
|
|
|
|
|